Close Menu

Fulgent Genetics: Brandon Perthuis

Mar 10, 2020

Fulgent Genetics has promoted Brandon Perthuis to chief commercial officer from VP of commercial operations. He will continue to lead the company's global sales organization and commercialization effort and will report to CEO Ming Hsieh. Perthuis came to Fulgent in 2017. He carries 16 years of experience in clinical genetics, including a stint as VP of sales and marketing at Baylor Genetics.

More Like This

May 29, 2020

OraSure Technologies: Lelio Marmora

OraSure Technologies has appointed Lelio Marmora as a member of the company's board of directors, effective June 1. Marmora previously served as executive director of Unitaid and also held senior positions at the Global Fund to Fight AIDS, TB and, Malaria.

May 29, 2020

Castle Biosciences: Federico Monzon

In a filing with the US Securities and Exchange Commission, Castle Biosciences said that Chief Medical Officer Federico Monzon notified the company on May 21 that he plans to resign, effective May 31. In November 2019, the firm had disclosed Monzon's intention to resign on or about April 1, 2020, but the move was subsequently delayed. 

May 28, 2020

Pacific Biosciences: Eric Schaefer

On May 26, Pacific Biosciences appointed Eric Schaefer to the role of vice president and chief accounting officer, effective immediately. He succeeds Susan Barnes as the principal accounting officer.

Schaefer previously served as PacBio's senior director, corporate controller. He joined the firm in 2012 from PricewaterhouseCoopers and is a certified public accountant.

May 28, 2020

Myriad Genetics: John Henderson, Daniel Spiegelman

Myriad Genetics said that John Henderson will retire from its board of directors at its annual meeting in December. Henderson chaired the board from April 2005 through March 2020, at which point Louise Phanstiel was elected to serve as chair. The company has also elected to its board of directors Daniel Spiegelman, who was most recently executive VP and CFO of BioMarin Pharmaceuticals. After retiring from that role, Spiegelman has been serving on the board of Tizona Therapeutics, as well on the boards of several biotech firms.

May 27, 2020

Flagship Biosciences: Aymii Couzelis

Flagship Biosciences has promoted Aymii Couzelis to CIO. As such, she will oversee scaling of technology across software development, the customer help desk, network engineering, project management, quality assurance, laboratory operations, and data security, the company said. Couzelis has been with Flagship Biosciences for about a year, previously as technology manager. She formerly was CIO of corporate wellness firm MediFit Corporate Services.

May 26, 2020

Progenity: Damon Silvestry

Molecular testing firm Progenity has appointed Damon Silvestry as its chief operating officer. Silvestry has more than 15 years of experience in strategic lab and business operations, including stints at Natera, Miraca Life Sciences, and Dell. He was most recently senior vice president, operations and people office at Natera.

May 26, 2020

Freenome: Bill Quirk, Gary Reedy

Freenome has hired Bill Quirk as its CFO. Prior to joining Freenome, Quirk served as a managing director in the equity research division of investment bank Piper Sandler. The company also announced that Gary Reedy has joined its board of directors as an observer. Reedy became CEO of the American Cancer Society in April 2015, having worked with the organization for more than 20 years. He has had a 37-year career as a healthcare business and advocacy leader, most recently as worldwide VP of government affairs and policy at Johnson & Johnson. He also held senior leadership positions with SmithKline Beecham, Centocor, and Johnson & Johnson.

May 20, 2020

Meridian Bioscience: Tony Serafini-Lamanna

Meridian Bioscience promoted Tony Serafini-Lamanna to executive VP of diagnostics, passing responsibility of the diagnostics division from CEO Jack Kenny and making Serafini-Lamanna an officer of the company. He was previously the global VP and general manager of diagnostics, a position he held since April 2018. The promotion became effective May 18. 

Before joining Meridian, Serafini-Lamanna worked at Siemens Healthcare Diagnostics as general manager for diagnostics Canada and VP of marketing for North America. 

May 19, 2020

Sema4: Martin Chavez

Sema4 has appointed Martin Chavez to its board of directors. Chavez served in several senior roles at the investment bank Goldman Sachs, including chief information officer, CFO, and global cohead of the firm's securities division. He was also a member of the firm's management committee.

Chavez cofounded Kiodex and Quorum Software Systems, which provide software for the finance and oil and gas industries, respectively.In addition to Sema4, Chavez serves on the boards of Paige, an AI biomedical tech startup, and Recursion, a software-based drug discovery company. This month he was named president of the Harvard Board of Overseers and serves on the Stanford Medicine board of fellows and the Institute for Advanced Study's board of trustees.

Chavez holds a master's degree in computer science from Harvard and a doctorate in Medical Information Sciences from Stanford University.

May 15, 2020

Centogene: Sun Kim, Oved Amitay

Sun Kim will become interim chief business officer of Centogene, effective June 1. He will replace Oved Amitay, who will leave the company on May 31, until a permanent chief business officer has been appointed. Kim is currently Centogene's chief strategy and investor relations officer. Prior to that, he was head of corporate strategy at Shire, and before that, he held multiple roles in the Alcon division of Novartis. Kim holds PhD and MS degrees in chemical engineering from Stanford University.

May 13, 2020

Thermo Fisher Scientific: Garret Hampton

Garret Hampton has been appointed as president of the clinical next-generation sequencing and oncology business at Thermo Fisher Scientific. He joins the firm from Illumina, where he was senior VP of clinical genomics. Before that, he was VP and global head of oncology biomarker development and companion diagnostics at Genentech. Hampton holds a PhD in cancer genetics from the University of London and an undergraduate degree in natural sciences from Trinity College Dublin.

May 12, 2020

Genentech: Aviv Regev

Aviv Regev will join Genentech as head of research and early development, effective August 1. She will replace Michael Varney, who will retire from his post at the end of July, and will also join Genentech's enlarged corporate executive committee. Regev is currently faculty chair, core institute member, and a member of the executive leadership team at the Broad Institute, as well as a professor of biology at the Massachusetts Institute of Technology and a Howard Hughes Medical Institute investigator. Prior to that, she was a Bauer fellow at the Center for Genomics Research at Harvard University. Regev holds a PhD in computational biology and a master of science degree from Tel Aviv University.

May 12, 2020

Seer: Omead Ostadan

Omead Ostadan will join Redwood City, California-based proteomics firm Seer as president and chief operating officer, effective June 29. He will also join the company's board of directors. Ostadan is currently chief product and marketing officer and a member of the executive management team of Illumina. He joined Illumina in 2007 as VP of marketing after the firm acquired Solexa, where he served in the same position. Prior to that, he held various marketing roles at Applied Biosystems. Ostadan holds a BS in biochemistry from the University of California, Davis, and an MBA from the Wharton School at the University of Pennsylvania.

May 12, 2020

Alveo Technologies: Bharat Tewarie

Alveo Technologies has appointed Bharat Tewarie to its board of directors. Tewarie recently founded Boston BioPharma Consultants and was formerly executive vice president and chief marketing officer at biopharma firm UCB. He currently is on the board of Ahara Biosciences and Duluth Medical Technologies. Alameda, California-based Alveo is developing an at-home diagnostic platform called be.well that leverages nucleic acid amplification for the molecular detection of infectious diseases.

May 12, 2020

Nucleix: Chris Hibberd, Todd Myers, Eyal Miller, Thomas Buchholz

Nucleix has appointed several individuals in executive and other leadership roles. The firm has appointed Chris Hibbered as CEO, while Opher Shapira will become a strategic business advisor to the firm. Hibberd previously served as CEO and cofounder of Astute Medical before it was acquired by bioMérieux. Prior to Astute Medical, Hibberd was senior VP of corporate development at Biosite Discovery.

The company has also appointed Todd Myers as CFO, and Eyal Miller as general manager for Europe, Middle East, and Africa, as well as managing the firm's operations in Rehovot, Israel.

Myers previously served as CFO of Astute Medical before it was acquired by bioMérieux. Before Astute, Myers was CFO at SGX Pharmaceuticals. He was also director of finance at CombiChem.

Before Nucleix, Miller served as VP and head of the healthcare division at Stratasys. Prior to Stratasys, Miller was CEO at Common Sense. Before working at Common Sense, Miller was a senior director and general manager of Europe at Touchstone International Medical Science Co.

Thomas Buchholz, who is currently the medical director of Scripps MD Anderson Cancer Center, will also join the firm's board. He served a six-year term as the co-chair of the Breast Cancer Steering COmmittee of the National Clinical Trials Network at the National Cancer Institute.

President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.

A study of Great Danes homes in on a genomic region linked to fearfulness.

CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.

In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.